New Kearney GBPC report, World in flux, highlights five wildcards that could dramatically shape the global outlook and the operating environment for business over the next five years
Study analyzes the rising power of the Global South, the increasing use of tariffs in international trade policy, and the growing influence of super-empowered individuals, among other issues. In this fast-changing global environment, strategic businesses will have to adapt and innovate to stay compe
HFSA and Elsevier Announce Inaugural Editor-in-Chief of New Journal of Cardiac Failure-Intersections
WASHINGTON, Jan. 10, 2025 /PRNewswire/ — The Heart Failure Society of America, in partnership with Elsevier, is proud to announce the appointment of Jason N. Katz MD, MHS (NYU Grossman School of Medicine, New York, NY) as the inaugural Editor-in-Chief of Journal of Cardiac Failure-Intersectio
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ — MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss
Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025
RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club
MIAMI, Jan. 10, 2025 /PRNewswire/ — HOPE Therapeutics™, Inc., (“HOPE”), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (“NRx”, and collectively with HOPE, the “Company”) (Nasdaq:NRXP), today announced it
XPPen Unveils Artist Pro 22 (Gen 2) with 2.5 K High-Performance 22-inch Drawing Display
LOS ANGELES, Jan. 10, 2025 /PRNewswire/ — Today, XPPen has officially launched a remarkable addition to its professional digital drawing display lineup: the Artist Pro 22 (Gen 2), a 22-inch unparalleled drawing display that ignites all-round performance, making it an ideal choice for artists
Is Spring Break 2025 the Most Expensive Yet? Here’s What You Need to Know
ST. PETERSBURG, Fla., Jan. 10, 2025 /PRNewswire/ — Students and families are eagerly counting down the days until spring break, which is shaping up to be both a busy and expensive travel season. With travelers spending more than ever on trips this spring break, Squaremouth, the nation’
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142, the “Company”), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncol
Bank of Montreal Enters into Automatic Securities Purchase Plan
TORONTO, Jan. 10, 2025 /PRNewswire/ – Bank of Montreal (TSX: BMO) (NYSE: BMO) today announced that it has entered into an automatic securities purchase plan (“ASPP”) with its broker, BMO Nesbitt Burns Inc., in order to facilitate repurchases of BMO common shares (“Comm
Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress
Announces Major Milestones at the JPM Healthcare Conference SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ — Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the company’s growth, sharpened focus on neuroscience
